Survivorship Study of Cancer Patients Who Received Cranial Radiation Therapy

Inclusion Criteria:

Cancer survivors who received cranial irradiation including, but not limited to, primary brain tumor, brain metastases, lung cancer receiving prophylactic brain irradiation, long-term survivors of pediatric cancers
Completed a course of fractionated partial brain irradiation, or whole brain irradiation, or stereotactic radiosurgery (for any modality at least a total cumulative dose of 20 Gy) more than 6 months prior to enrollment
Age ≥ 18 years at the time of entry into the study
Karnofsky performance score (KPS) ≥ 70 or Eastern Cooperative Oncology Group (ECOG) grade ≤ 2.
No imaging evidence of disease progression within 4 months of enrollment
Life expectancy > 6 months
Access to a smartphone, tablet, or computer with capability to utilize the mobile symptom-tracking application
Signed informed consent approved by the Institutional Review Board
Subject must be fluent in English

Exclusion Criteria:

Active psychiatric illness
Clinically significant renal disease or insufficiency at the time of screening
History of severe liver disease or laboratory values for liver function tests > 2.5 times the upper limit of normal at screening
Use of cognition-enhancing medications at the time of screening. If patients have used cognition-enhancing medications in the past, a wash-out period can be considered for screening of 8 weeks at the discretion of the PI.
Allergy to Namzaric or any of the components of Namzaric.
Pregnancy